China Pharma (CPHI) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
China Pharma (CPHI) has outperformed Zhengye Biotechnology (ZYBT) over the past year, losing 56.6% versus a loss of 62.7%. Zhengye Biotechnology is the larger company by market cap ($54.5 million vs $41.3 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPHI | ZYBT |
|---|---|---|
| Share price | $0.96 | $1.15 |
| Market cap | $41.30M | $54.50M |
| 1-day change | +12.94% | -0.87% |
| YTD return | -29.75% | -0.01% |
| 1-year return | -56.63% | -62.67% |
| 5-year return | -99.69% | — |
| EPS (TTM) | $-0.42 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.19 | $8.01 |
| 52-week low | $0.38 | $0.616 |
| Distance from 52-week high | -95.00% | -85.64% |
| Average volume | 5.47M | 5.11M |
| Shares outstanding | 43.02M | 47.39M |
| Employees | 215 | 269 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About China Pharma
CPHI stock →China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.
Healthcare · Drug Manufacturers - Specialty & Generic · 215 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Healthcare · Drug Manufacturers - Specialty & Generic · 269 employees
CPHI vs ZYBT FAQ
Which is bigger, China Pharma or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $54.50M compared with $41.30M for China Pharma (CPHI).
Which stock has performed better over the past year, CPHI or ZYBT?
CPHI returned -56.63% over the past 12 months, compared with -62.67% for ZYBT (price return, excluding dividends). Past performance does not predict future results.
Are China Pharma and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.